Inactivation of Glis2 suppresses polycystic kidney disease in mouse models of ADPKD, and pharmacological targeting of Glis2 with antisense oligonucleotides slows disease progression. This evidence concerns the gene GLIS2 and autosomal dominant polycystic kidney disease.